Opinion|Videos|June 24, 2024
MajesTEC-1: Efficacy and Safety of Teclistamab
Author(s)Amrita Y. Krishnan, MD, Binod Dhakal, MD, MS
Experts on multiple myeloma review the study design and results from MajesTEC-1, focusing on the efficacy and safety findings, and provide insights on adverse event management practices.
Advertisement
Video content above is prompted by the following question:
- What were the efficacy and safety findings from the long-term follow-up from MajesTEC-1?
Advertisement
Related to this article
Hematologic specialists discussed where ciltacabtagene autoleucel fits in the treatment paradigm at first relapse and beyond in multiple myeloma.
Updated NCCN Guidelines for multiple myeloma add a dedicated MRD testing framework and expand recommended MRD assessment timepoints.
Experts discussed whether CAR T cells or bispecific antibodies should be used first in relapsed/refractory multiple myeloma at the 2026 SOHO Annual Meeting.